Clinical Trial Update: Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

View source ↗

Summary

Clinical trial results report the efficacy of combining Target immunotherapy with XELOX chemotherapy in advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Eloxatin (oxaliplatin) (oxaliplatin)
• Target - Immunotherapy
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Advanced HCC, Systemic Therapy | Status: COMPLETED